Sydney, February 15, 2026, 17:20 AEDT — The session wrapped up with the market now closed.
- Pro Medicus (ASX:PME) slipped 8.4% on Friday, finishing the session at A$118.22.
- After releasing its half-year update, the stock tumbled roughly 30% over two sessions.
- Traders are eyeing new broker notes, with the 32 Australian cents payout going ex-dividend on Feb. 26.
Pro Medicus (ASX:PME) closed out Friday at A$118.22, falling 8.4% and deepening a two-day slide triggered by its half-year results. Shares in the radiology software firm have now lost roughly 30% since Wednesday’s close, with volume on Friday hitting around 1.46 million.
The selloff has spread beyond just one stock, drawing in local funds as well. Pro Medicus, a healthcare software firm known for its hefty margins, was priced for perfection—until the last two days, which rattled that confidence.
The ASX was closed all weekend, so Monday’s opening will finally show if the recent drop was just some portfolio tidying—or a sign of something deeper. Whatever the answer, this name shifts from a simple hold to something worth watching closely.
Pro Medicus on Thursday posted a 28.4% increase in revenue from ordinary activities, hitting A$124.8 million. Underlying profit before tax, with investment revaluations excluded, climbed 29.7% to A$90.7 million. Net profit after tax came in at A$171.2 million, buoyed by unrealised gains tied to the company’s stake in 4D Medical. The board declared a fully franked interim dividend of 32 Australian cents per share. “Our profits continue to grow strongly,” CEO Dr Sam Hupert said, adding that revenue would ramp up as new projects are brought online. He highlighted a contract pipeline with new hospital deals that carry minimum commitments over A$280 million. Company Announcements
Brokers wasted no time reacting to the result. Bell Potter slashed its price target to A$240, down from A$320. RBC Capital Markets also pared its target, setting it at A$190 from the previous A$225. E&P, meanwhile, trimmed its target but held onto a neutral view, Market Index’s broker summary showed.
Laura Sutcliffe at Citi flagged that the A$125 million in revenue landed 5% shy of what analysts had penciled in, and underlying EBIT fell short by 14%, according to ShareCafe.
It’s been a tough stretch for Australia’s “software-like” stocks, too, with the latest move hitting a nervous market. WiseTech Global and Xero have both dropped, Market Index reported, as global AI concerns put the squeeze on valuation multiples and left little room for any slip in earnings. Market Index
Pro Medicus could run into trouble if project rollouts fall behind, delaying when revenues hit the books—investors don’t usually wait around for clarity and could keep pushing the shares lower until those new contract go-lives show up in the numbers. If it turns out that premium pricing scares off potential clients, that’s just more fuel for the selloff.
The dividend calendar is coming up fast. S&P Capital IQ data points to the interim dividend going ex-dividend on Feb. 26—investors need to own shares before this date to qualify. Feb. 27 marks the record date, and the payment lands on March 20.
